KROS
Keros Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +4.9% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 14.96K | $174,181 | n/a | n/a |
| Q2 2026 | 68 | -2 | 12.51M | $133.89M | +5 | −7 |
| Q1 2026 | 72 | +4 | 12.53M | $138.59M | +8 | −4 |
| Q4 2025 | 68 | +1 | 14.80M | $301.38M | +1 | n/a |
| Q3 2025 | 16 | 0 | 12.05M | $190.67M | n/a | n/a |
| Q2 2025 | 13 | +1 | 9.42M | $125.76M | +2 | −1 |
| Q1 2025 | 9 | -1 | 3.92M | $39.99M | +1 | −2 |
| Q4 2024 | 10 | 0 | 4.67M | $74.00M | +1 | −1 |
| Q3 2024 | 9 | -1 | 4.72M | $274.14M | +1 | −2 |
| Q2 2024 | 10 | n/a | 3.52M | $160.87M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 2.72M | +3.3% | $43.01M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 2 | BlackRock ✦ (passive) | 2.72M | -0.6% | $42.99M | 0.0% | ▼ Trim | 2 | SEC ↗ ×9 |
| 3 | D. E. Shaw & Co. ✦ | 1.33M | +2.6% | $21.06M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 4 | Goldman Sachs Group ✦ | 1.33M | n/a | $20.97M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 5 | State Street Global Advisors ✦ (passive) | 1.30M | -5.9% | $20.61M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 837.36K | +1.0% | $13.25M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Morgan Stanley ✦ | 395.10K | n/a | $6.25M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 8 | JPMorgan Chase ✦ | 343.88K | n/a | $5.44M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 9 | Arrowstreet Capital ✦ | 258.75K | +300.7% | $4.09M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 204.35K | +189.2% | $3.23M | 0.0% | ▲ Add | 3 | SEC ↗ ×5 |
| 11 | Citadel Advisors ✦ | 176.14K | +669.2% | $2.79M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 12 | Renaissance Technologies ✦ | 154.70K | +5.5% | $2.45M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 100.53K | -38.8% | $1.59M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 14 | Two Sigma Investments ✦ | 82.52K | +510.3% | $1.31M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | Millennium Management ✦ | 53.35K | +289.2% | $843,934 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 49.98K | +3.2% | $791,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 149 holders, 18.56M shares, $201.20M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 1.00K sh @ 10.27 · $10,270
Open-market sales (S)
Officer · 4.49K sh · $46,151
Director · 551 sh · $5,675
Officer · 3.57K sh · $36,715
Officer · 1.22K sh · $12,595
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology